180 Life Sciences Corp (ATNF)

$2.3

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $2.21
    $2.41
    $2.30
    downward going graph

    3.91%

    Downside

    Day's Volatility :8.29%

    Upside

    4.56%

    downward going graph
  • $1.31
    $21.28
    $2.30
    downward going graph

    43.04%

    Downside

    52 Weeks Volatility :93.84%

    Upside

    89.19%

    downward going graph

Returns

Period180 Life Sciences CorpRussel 2000Index (Russel 2000)
3 Months
27.78%
0.0%
0.0%
6 Months
-47.28%
0.0%
0.0%
1 Year
-86.7%
0.0%
0.0%
3 Years
-99.93%
-20.2%
-20.2%

Highlights

Market Capitalization
2.1M
Book Value
- $1.12
Earnings Per Share (EPS)
-30.12
Wall Street Target Price
80.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-73.28%
Return On Equity TTM
-525.19%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-10.7M
Diluted Eps TTM
-30.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for 180 Life Sciences Corp(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3378.26%

Current $2.30
Target $80.00

Technicals Summary

Sell

Neutral

Buy

180 Life Sciences Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
180 Life Sciences Corp
180 Life Sciences Corp
50.33%
-47.28%
-86.7%
-99.93%
-78.05%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
180 Life Sciences Corp
180 Life Sciences Corp
3.47
NA
NA
0.0
-5.25
-0.73
NA
-1.12
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
180 Life Sciences Corp
180 Life Sciences Corp
Buy
$2.1M
-78.05%
3.47
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on 180 Life Sciences Corp

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 148.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 286.4%

Institutional Holdings

  • Charles Schwab Investment Management Inc

    1.95%

  • Tower Research Capital LLC

    0.37%

  • Vanguard Group Inc

    0.27%

  • BlackRock Inc

    0.08%

Company Information

180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.

Organization
180 Life Sciences Corp
Employees
4
CEO
Dr. Lawrence Steinman BA, M.D., Ph.D.
Industry
Finance

Discover More

FAQs